U.S. Markets open in 4 hrs 42 mins
  • S&P Futures

    3,942.75
    +45.00 (+1.15%)
     
  • Dow Futures

    31,484.00
    +282.00 (+0.90%)
     
  • Nasdaq Futures

    12,079.00
    +200.75 (+1.69%)
     
  • Russell 2000 Futures

    1,799.70
    +24.80 (+1.40%)
     
  • Crude Oil

    111.65
    -0.56 (-0.50%)
     
  • Gold

    1,843.00
    +1.80 (+0.10%)
     
  • Silver

    21.98
    +0.07 (+0.31%)
     
  • EUR/USD

    1.0581
    -0.0007 (-0.0635%)
     
  • 10-Yr Bond

    2.8550
    0.0000 (0.00%)
     
  • Vix

    28.51
    -2.45 (-7.91%)
     
  • GBP/USD

    1.2485
    +0.0010 (+0.0787%)
     
  • USD/JPY

    128.0460
    +0.2520 (+0.1972%)
     
  • BTC-USD

    30,287.21
    +1,181.58 (+4.06%)
     
  • CMC Crypto 200

    675.06
    +22.83 (+3.50%)
     
  • FTSE 100

    7,411.70
    +108.96 (+1.49%)
     
  • Nikkei 225

    26,739.03
    +336.19 (+1.27%)
     

If You Had Bought Rigel Pharmaceuticals (NASDAQ:RIGL) Stock A Year Ago, You Could Pocket A 49% Gain Today

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But one can do better than that by picking better than average stocks (as part of a diversified portfolio). To wit, the Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) share price is 49% higher than it was a year ago, much better than the market return of around 22% (not including dividends) in the same period. That's a solid performance by our standards! Zooming out, the stock is actually down 13% in the last three years.

View our latest analysis for Rigel Pharmaceuticals

Because Rigel Pharmaceuticals made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

Over the last twelve months, Rigel Pharmaceuticals' revenue grew by 30%. That's a fairly respectable growth rate. Buyers pushed the share price 49% in response, which isn't unreasonable. If the company can maintain the revenue growth, the share price could go higher still. But before deciding this growth stock is underappreciated, you might want to check out profitability trends (and cash flow)

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

If you are thinking of buying or selling Rigel Pharmaceuticals stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

It's good to see that Rigel Pharmaceuticals has rewarded shareholders with a total shareholder return of 49% in the last twelve months. That's better than the annualised return of 5% over half a decade, implying that the company is doing better recently. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that Rigel Pharmaceuticals is showing 1 warning sign in our investment analysis , you should know about...

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.